GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (NAS:ADPT) » Definitions » EPS without NRI

Adaptive Biotechnologies (Adaptive Biotechnologies) EPS without NRI : $-1.56 (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies EPS without NRI?

Adaptive Biotechnologies's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.48. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.56.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -7.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Adaptive Biotechnologies's EPS without NRI or its related term are showing as below:

ADPT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -49.9   Med: -26.2   Max: -7.6
Current: -7.6

During the past 7 years, Adaptive Biotechnologies's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -7.60% per year. The lowest was -49.90% per year. And the median was -26.20% per year.

ADPT's 3-Year EPS without NRI Growth Rate is ranked worse than
65.02% of 1295 companies
in the Biotechnology industry
Industry Median: 4.7 vs ADPT: -7.60

Adaptive Biotechnologies's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.48. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.56.

Adaptive Biotechnologies's EPS (Basic) for the three months ended in Dec. 2023 was $-0.48. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.56.


Adaptive Biotechnologies EPS without NRI Historical Data

The historical data trend for Adaptive Biotechnologies's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies EPS without NRI Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -1.01 -1.11 -1.48 -1.40 -1.38

Adaptive Biotechnologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.40 -0.33 -0.35 -0.48

Competitive Comparison of Adaptive Biotechnologies's EPS without NRI

For the Biotechnology subindustry, Adaptive Biotechnologies's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptive Biotechnologies's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's PE Ratio without NRI falls into.



Adaptive Biotechnologies EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adaptive Biotechnologies  (NAS:ADPT) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Adaptive Biotechnologies EPS without NRI Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptive Biotechnologies (Adaptive Biotechnologies) Business Description

Traded in Other Exchanges
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").
Executives
Kyle Piskel officer: Principal Accounting Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Nitin Sood officer: Chief Commercial Officer, MRD C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Tycho Peterson officer: Chief Financial Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
R Mark Adams officer: Chief Operating Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Stacy L Taylor officer: SVP and General Counsel C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102
Leslie Trigg director C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112
Kevin T Conroy director 5505 ENDEAVOR LANE, MADISON WI 53719
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Peter M Neupert director 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Sharon Benzeno officer: Chief Commercial Ofc Imm Med C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Harlan S Robins officer: Chief Scientific Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Francis Lo officer: Chief People Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michael J Pellini director 222 DUTTON MILL RD, WILLISTOWN PA 19380
Chad M Robins director, officer: CEO and Chairman C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102

Adaptive Biotechnologies (Adaptive Biotechnologies) Headlines

From GuruFocus